secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-268134
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Whitehawk Therapeutics reports Q3 net loss of $17.7M, cash $162.6M, IND filings on track
--------------------------------------------------------------------------------

- Net loss for Q3 2025 was $17.7M vs $12.5M in Q3 2024; no revenue reported.
- Cash, equivalents and short-term investments $162.6M as of Sept 30, 2025, up from $47.2M at Dec 31, 2024; runway into 2028.
- IND submissions for HWK-007 and HWK-016 planned by year-end 2025; HWK-206 by mid-2026.
- PTK7 confirmed as broadly expressed tumor target through analysis presented at AACR-NCI-EORTC.
- Management expects initial clinical data readouts across portfolio from current cash position.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312525268134/0001193125-25-268134-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312525268134/whwk-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-268134

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer